2026-05-31T17:00:35Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/325822026-02-03T10:59:56Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Fernández Fernández, Óscar author Mayorga Mayorga, Cristobalina author Luque, Gloria author Guerrero, Miguel author Guerrero, Rocío author Leyva-Fernández, Laura author León-Martín, Antonio author Blanca, Miguel author 2001 Interferon (IFN)-β is generally considered an effective treatment for multiple sclerosis (MS); however, some patients do not respond to this therapy, possibly due to the production of neutralising antibodies (NAB) which can prevent the biological effect of IFN-β. We compared the two types of IFN-β, the glycosylated IFN-β1a and the non-glycosylated IFN-β1b, as their chemical differences may entail differing immunogenic capacities. We studied 22 relapsing-remitting MS patients treated with IFN-β1a and 31 treated with IFN-β1b for 1 year, using the same assay and criteria, to compare the two types of IFN-β in their ability to induce binding and neutralising antibodies and examined the correlation of the findings with the clinical data. Binding antibodies to IFN-β1a and IFN-β1b were determined by enzyme-linked immunosorbent assay. A bioassay was used to detect and quantify the NABs to IFN-β, measuring the capacity of NABs to block the antiviral resistance induced by IFNs. Binding antibodies were found in 32% of those treated with IFN-β1a and in 52% of those treated with IFN-β1b; NABs were found in 14% and 24%, respectively. Both groups showed a significant decrease in relapse rate during the first year of treatment. These results demonstrate that the IFN-β1b molecule is more immunogenic than the IFN-β1a molecule. This may be due to the non-glycosylated, chemical structure of the former, which can produce aggregates and enhance antibody production. No association was found between the presence of NABs and the clinical status of the patients. Fernández O, Mayorga C, Luque G, Guerrero M, Guerrero R, Leyva L, León A, Blanca M. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. J Neurol. 2001 May;248(5):383-8. https://hdl.handle.net/10630/32582 10.1007/s004150170178 Esclerosis múltiple - Tratamiento Study of binding and neutralising antibodies to interferon-β in two groups of relapsing-remitting multiple sclerosis patients.